Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01893294 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01893294: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01893294 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01893294, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of gemcitabine hydrochloride in treating patients with locally advanced pancreatic cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Interventions
- OTHER laboratory biomarker analysis
- DRUG fluorouracil
- RADIATION radiation therapy
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01893294
The ClinicalTrials.gov registry entry for NCT01893294 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01893294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01893294 about?
NCT01893294 is a clinical study titled "Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer". This phase I trial studies the side effects and best dose of gemcitabine hydrochloride in treating patients with locally advanced pancreatic cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or...
What is the current status of trial NCT01893294?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2013-04. Estimated completion is 2015-10-30.
What interventions are being tested in trial NCT01893294?
The interventions under investigation include: laboratory biomarker analysis (OTHER), fluorouracil (DRUG), radiation therapy (RADIATION), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01893294?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.